Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: A systematic review

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 485-496

  Johnson, Kent R ^a   Liauw, W ^a   Lassere, M N D ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Metastatic renal cell; Progression free survival; Surrogate marker; Surrogate threshold effect; Targeted therapy

Indexed keywords

AE 941; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARNITINE; DEHYDRODIDEMNIN B; EVEROLIMUS; FLUOROURACIL; GAMMA INTERFERON; HISTAMINE; INTERFERON; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PAZOPANIB; PLACEBO; RETINOIC ACID; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; VINBLASTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; TIVOZANIB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG MEGADOSE; HUMAN; KIDNEY METASTASIS; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; SYSTEMATIC REVIEW; CARCINOMA, RENAL CELL; DISEASE COURSE; DISEASE FREE SURVIVAL; EVALUATION STUDY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PHENYLUREA COMPOUNDS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84939796768     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu267     Document Type: Review

References (82)

1. Gleave ME, Elhilali M, Fradet Y et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338(18): 1265-1271.
2. Kane RC, Farrell AT, Saber H et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12(24): 7271-7278.
3. Goodman VL, Rock EP, Dagher R et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13(5): 1367-1373.
4. Nieto M, Borregaard J, Ersboll J et al. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the committee for medicinal products for human use. Clin Cancer Res 2011; 17(21): 6608-6614.
5. FDA. Axitinib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289439.htm (21 January 2013, date last accessed).
6. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15(4): 428-435.
7. FDA. Everolimus 2010. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedical ProductsandTobacco/CDER/ucm127799.htm (21 January 2013, date last accessed).
8. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010; 15(1): 104-111.
9. U.S. Food and Drug Administration & ASCO, Co-sponsored by the American Association for Cancer Research. Ovarian Cancer Endpoints Workshop April 26, 2006 MEETING SUMMARY. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf (21 January 2013, date last accessed).
10. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25(29): 4562-4568.
11. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25(33): 5218-5224.
12. Giusti RM, Shastri KA, Cohen MH et al. FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007; 12(5): 577-583.
13. Sridhara R, Johnson JR, Justice R et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 2010; 102(4): 230-243.
14. McKee AE, Farrell AT, Pazdur R, Woodcock J. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist 2010; 15(Suppl 1): 13-18.
15. Coppin C, Kollmannsberger C, Le L et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011; 108(10): 1556-1563.
16. Burzykowski T, Molenberghs G, Buyse ME. The Evaluation of Surrogate Endpoints. New York: Springer 2005.
17. Micheel C, Ball J. Institute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington, DC, National Academies Press 2010.
18. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997; 16(17): 1965-1982.
19. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008; 17(3): 303-340.
20. Lassere MN, Johnson KR, Schiff M, Rees D. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). BMC Med Res Methodol 2012; 12: 27.
21. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988; 57(6): 615-618.
22. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br J Med 2009; 339: b2700-b.
23. Coppin C, Le L, Tilt T, Kollmannsberger C. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008 (2): CD006017.
24. Coppin C, Prozsolt R, Autenreith M et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2004 (3): CD001425.
25. Boccardo F, Rubagotti A, Canobbio L et al. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial. Tumori 1998; 84(5): 534-539.
26. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais D'immunotherapie. N Engl J Med 1998; 338(18): 1272-1278.
27. Collaborators MRCRC. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353(9146): 14-17.
28. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17(9): 2859-2867.
29. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18(16): 2972-2980.
30. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais D'immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000; 18(24): 4009-4015.
31. Atzpodien J, Kirchner H, Illiger HJ et al. Il-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85(8): 1130-1136.
32. Dutcher JP, Fine JP, Krigel RL et al. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma. Med Oncol 2003; 20(3): 271-281.
33. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5): 427-434.
34. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2-and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy group. J Clin Oncol 2004; 22(7): 1188-1194.
35. Aass N, De Mulder PH, Mickisch GH et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005; 23(18): 4172-4178.
36. Donskov F, Middleton M, Fode K et al. Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer 2005; 93(7): 757-762.
37. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23(1): 133-141.
38. Atzpodien J, Kirchner H, Rebmann U et al. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy group (DGCIN). Br J Cancer 2006; 95(4): 463-469.
39. Tannir NM, Cohen L, Wang X et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107(9): 2254-2261.
40. Ebbinghaus S, Hussain M, Tannir N et al. Phase 2 study of abt-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007; 13(22 Pt 1): 6689-6695.
41. Escudier B, Venner P, Bukowski R et al. Phase III trial of Neovastaat in metastatic renal cell carcinoma patients refractory to immunotherapy. J Clin Oncol 2003; 22 (suppl): abstract 844.
42. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
43. Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110(11): 2468-2477.
44. Negrier S, Perol D, Ravaud A et al. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res 2008; 14(18): 5907-5912.
45. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27(20): 3312-3318.
46. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-3590.
47. Schoffski P, Guillem V, Garcia M et al. Phase II randomized study of plitidepsin (aplidin), alone or in association with l-carnitine, in patients with unresectable advanced renal cell carcinoma. Mar Drugs 2009; 7(1): 57-70.
48. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28(13): 2144-2150.
49. Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010; 375(9715): 641-648.
50. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116(18): 4256-4265.
51. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28(13): 2137-2143.
52. Liu L, Zhang W, Qi X et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012; 18(6): 1751-1759.
53. Motzer RJ, Hutson TE, Olsen MR et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30(12): 1371-1377.
54. Therasse P, Arbuck S, Eisenhauer E et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205-216.
55. Chakravarty A, Sridhara R. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res 2008; 17(5): 515-518.
56. Rock EP, Goodman V, Jiang JX et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12(1): 107-113.
57. Fleming T, DeMets D. Surrogate endpoints in clinical trials: are we being misled? Ann Int Med 1996; 125: 605-613.
58. Halabi S, Rini B, Escudier B et al. Progression-free survival as a surrogate endpoint of overall survival in patiens with metastatic renal cell carcinoma. Cancer 2014; 120: 52.
59. Becker A, Eichelberg C, Sun M. Editorial: progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer 2014; 120: 7-10.
60. Prentice R. Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med 1989; 8: 431-440.
61. Boissel J, Collet J, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
62. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790-795.
63. Bucher H, Guyatt G, Cook D et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771-778.
64. De Gruttola VG, Clax P, DeMets DL et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22(5): 485-502.
65. Lassere M, Johnson K, Boers M et al. Definitions and validation criteria for biomarker and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007; 34(3): 607-615.
66. Johnson K, Ringland C, Stokes B et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7(9): 741-746.
67. Delea TE, Khuu A, Hay A et al. Association between treatment effects on disease progression DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009; 27: 15s; (suppl); abstr 5105.
68. Heng DY, Xie W, Bjarnason GA et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011; 117(12): 2637-2642.
69. Sargent D, Wieand S, Benedetti J et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials. Associated Presentation at American Society of Clinical Oncology 2004 Annual Meeting; http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-009587,00.asp (15 January 2013, date last accessed).
70. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to firstline chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356(9227): 373e8.
71. Johnson KR, Freemantle N, Anthony DM, Lassere MN. LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE). J Clin Epidemiol 2009; 62(3): 328-336.
72. Amit O, Bushnell W, Dodd L et al. Blinded independent central review of the progression-free survival endpoint. Oncologist 2010; 15(5): 492-495.
73. Dodd LE, Korn EL, Freidlin B et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008; 26(22): 3791-3796.
74. Freidlin B, Korn EL, Hunsberger S et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007; 25(15): 2122-2126.
75. Stone AM, Bushnell W, Denne J et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur J Cancer 2011; 47(12): 1763-1771.
76. FDA_axitinib_BriefingDoc_2011_NDA 202324_ucm282290.pdf; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM282290.pdf (20 January 2013, date last accessed).
77. RESEARCH FADACFDEA. ONCOLOGIC DRUGS ADVISORY COMMITTEE (ODAC) MEETING (axitinib_transcript_FDA_2011_UCM288716.pdf ) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM288716.pdf (20 January 2013, date last accessed).
78. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378(9807): 1931-1939.
79. Robins J, Tsiatis A. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 1991; 20: 2609-2631.
80. Morden JP, Lambert PC, Latimer N et al. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Med Res Methodol 2011; 11: 4.
81. Korn EL, Freidlin B, Abrams J. Overall survival as the outcome for randomized clinical trials with effecitve subsequent therapies. J Clin Oncol 2011; 29(17): 2439-2442.
82. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27(17): 2874-2880.